Niki BioSolutions, Inc. 8K

The 8-K files an investor presentation describing Niki BioSolutions and its completed all-stock merger between Aptorum Group and DiamiR Biosciences, outlining ownership split, business strategy, and product pipeline.

The Form 8-K includes as Exhibit 99.1 an investor presentation for Niki BioSolutions, the post-merger company formed through an all‑stock merger between Aptorum Group Limited and DiamiR Biosciences Corp., noting that the merger closed on July 20, 2026 with DiamiR shareholders owning approximately 70% and Aptorum shareholders owning approximately 30% of the combined NASDAQ‑listed company (ticker NIKI), and describing the company’s strategy, diagnostics‑focused business model, development pipeline, and planned revenue streams from pharma and clinical services in Alzheimer’s disease and related indications.

Filing Facts

CIK

1734005

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-099695

Alert Tier

7